Landos Biopharma

Please note: The information displayed on this page might be outdated.
Landos Biopharma: Landos Biopharma is a clinical-stage biopharmaceutical company which uses its LANCE A.I. platform to discover and develop novel, first-in-class oral therapeutics for autoimmune diseases. Lead asset omilancor (BT-11) is a Phase 3-ready orally-active, gut-restricted candidate for treatment of ulcerative colitis also targeting Crohn’s disease and IBS. NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway (UC Ph1b initiated 2Q21, topline data 1H22). Additional candidates are in development for the treatment of lupus nephritis (IND accepted in Oct. 2021), rheumatoid arthritis, multiple sclerosis, and diabetes. Partnership with LianBio to develop and commercialize Omilancor and NX-13 in greater China and select Asian markets announced May 2021.
Based in...
US - South Atlantic
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Gastrointestinal, Metabolic Disorders
Public, USA
Market Cap
1800 Kraft Drive SW
Suite 216
Blacksburg, VA 24060
United States

Company Participants at Solebury Trout Hamptons CEO Roundtable 2021

  • Josep Bassaganya-Riera, Chairman of the Board, President & CEO
  • Jyoti Chauhan, Executive Director, Global Clinical Operations & Regulatory Compliance
  • Marek Ciszewski, VP of Financial Strategy and Investor Relations

Lead Programs


Indication Phase


Indication Phase


Indication Phase
LANCL2 Pre-clinical
LANCL2 Pre-clinical

Top 10 Holders of Landos Biopharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Perceptive Advisors LLC 36.94 14,869,915 10.40 13F 3/31/22
RTW Investments LP 10.62 4,275,722 2.99 13F 3/31/22
OUP Management Co. LLC 4.54 1,827,478 1.28 13F 3/31/22
BlackRock Fund Advisors 1.06 426,448 0.30 13F 3/31/22
Renaissance Technologies LLC 0.85 340,500 0.24 13F 3/31/22
OrbiMed Advisors LLC 0.70 283,217 0.20 13F 3/31/22
JPMorgan Investment Management, Inc. 0.66 264,108 0.18 13F 3/31/22
The Vanguard Group, Inc. 0.40 159,893 0.11 Funds 4/30/22
Bridgeway Capital Management LLC 0.39 159,000 0.11 13F 3/31/22
Jacobs Levy Equity Management, Inc. 0.39 158,875 0.11 13F 3/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.